• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

China Aoxing Phamaceutical Company to Present at the UBS Global Generic and Specialty Pharmaceuticals Conference

Posted on: Monday, 7 May 2007, 09:00 CDT

NEW YORK, May 7 /PRNewswire-FirstCall/ -- China Aoxing Pharmaceutical Company, Inc. (BULLETIN BOARD: CAXG) , one of the first non-governmental enterprises to enter the analgesic industry in China, today announced that the Company will attend the UBS Global Generic and Specialty Pharmaceuticals Conference on May 8, 2007 at the Grand Hyatt in New York City, NY. Management is currently scheduled to present at 3:00 pm ET. Listeners may access a live webcast of the presentation by visiting http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20070508.

Investors who would like more information about attending the UBS Global Generic and Specialty Pharmaceuticals Conference should contact their UBS sales representative.

About China Aoxing Pharmaceutical Group

China Aoxing Pharmaceutical Company, Inc. (BULLETIN BOARD: CAXG) acquired Hebei Aoxing Pharmaceutical Group Co. Ltd in a reverse merger transaction in April of 2006. Hebei Aoxing Pharmaceutical Group is a corporation organized under the laws of the People's Republic of China that has developed a patented manufacturing process for a variety of generic analgesic drugs, including Oxycodone, Pholcodine, Naloxone, and Tilidine. Hebei Aoxing is one of only a handful of companies in China to be granted the license to manufacture these drugs and is working closely with the Chinese government to assure their availability throughout China.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. You are urged to read the Company's filings with the Securities and Exchange Commission, including, but not limited to, the risk factors contained therein. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

CONTACT Dr. Hui Shao Senior Vice President China Aoxing Pharmaceutical 201-420-1075 Ashley Ammon MacFarlane & Bill Zima Integrated Corporate Relations, Inc. 203-682-8200

China Aoxing Pharmaceutical Group

CONTACT: Dr. Hui Shao, Senior Vice President of China AoxingPharmaceutical, +1-201-420-1075; or Ashley Ammon MacFarlane, Bill Zima,+1-203-682-8200, both of Integrated Corporate Relations, Inc., both for ChinaAoxing Pharmaceutical

Source: PRNewswire-FirstCall

More News in this Category